所有图片(1)
About This Item
经验公式(希尔记法):
C16H14N2O4
CAS号:
分子量:
298.29
MDL编号:
UNSPSC代码:
12352200
PubChem化学物质编号:
NACRES:
NA.77
推荐产品
方案
≥98% (HPLC)
表单
powder
颜色
yellow
溶解性
DMSO: ≥10 mg/mL
储存温度
2-8°C
SMILES字符串
COc1ccc(cc1)-n2c(C)c([N+]([O-])=O)c3ccc(O)cc23
InChI
1S/C16H14N2O4/c1-10-16(18(20)21)14-8-5-12(19)9-15(14)17(10)11-3-6-13(22-2)7-4-11/h3-9,19H,1-2H3
InChI key
VVZNWYXIOADGSW-UHFFFAOYSA-N
一般描述
ID-8 是双特异性酪氨酸磷酸化调节激酶 1A (DYRK1A) 的抑制剂。
生化/生理作用
ID-8 在体外维持小鼠胚胎干细胞 (ESC) 的自我更新和多潜能性。以稳定的速度刺激增殖(在添加 10 μg/ml 的无血清培养基中观察到)M 为期 30 天)。
在体外维持小鼠胚胎干细胞 (ESC) 的自我更新和多能性。
储存分类代码
11 - Combustible Solids
WGK
WGK 3
Stefan Hindel et al.
PloS one, 10(6), e0128060-e0128060 (2015-06-11)
The purpose of our study was to validate perfusion quantification in a low-perfused tissue by dynamic contrast-enhanced magnetic resonance imaging (DCE-MRI) with shared k-space sampling using a blood pool contrast agent. Perfusion measurements were performed in a total of seven
Yusuke Higuchi et al.
Current molecular pharmacology, 9(3), 272-279 (2015-05-27)
Despite their high degree of identity and even higher homology, the two Kat3 transcriptional coactivators, CBP and p300, have distinct functions, particularly within the Wnt/β-catenin signaling cascade. ICG-001, by directly binding to CBP but not p300, inhibits CBP/β-catenin transcription and
A High-Throughput Screen Identifies DYRK1A inhibitor ID-8 that Stimulates Human Kidney Tubular Epithelial Cell Proliferation
Monteiro M B, et al.
Journal of the American Society of Nephrology, ASN-2018040392 (2018)
Jin Zhou et al.
Annals of translational medicine, 8(12), 752-752 (2020-07-11)
Paclitaxel is a widely used clinical first line chemotherapy drug for ovarian carcinoma. Tanshinone I (Tan-I) is one of the vital fat-soluble components, which derived from Chinese herbal medicine, Salvia miltiorrhiza Bunge. Herein, we evaluated whether Tan-I could enhance the
Amy A Lo et al.
Molecular cancer therapeutics, 20(4), 716-725 (2021-02-05)
Ovarian cancer is a diverse class of tumors with very few effective treatment options and suboptimal response rates in early clinical studies using immunotherapies. Here we describe LY6/PLAUR domain containing 1 (LYPD1) as a novel target for therapeutic antibodies for
我们的科学家团队拥有各种研究领域经验,包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.
联系技术服务部门